人顶体酶活性腔性质及与抑制剂的结合模式

高等学校化学学报 ›› 2009, Vol. 30 ›› Issue (12): 2409.

人顶体酶活性腔性质及与抑制剂的结合模式

张珏, 郑灿辉, 盛春泉, 周有骏, 朱驹, 吕加国

第二军医大学药学院药化教研室, 上海 200433

收稿日期:2009-03-18 出版日期:2009-12-10 发布日期:2009-12-10
通讯作者: 吕加国, 男, 副教授, 主要从事抗生育药物的设计与合成. E-mail: ljg20060508@yahoo.com.cn
基金资助:
上海市计生委科研基金(批准号: 2007JG02)和上海市重点学科建设项目(批准号: B906)资助.

Characterization of Human Acrosin Active Site and Binding Modes with Its Inhibitors

ZHANG Jue, ZHENG Can-Hui, SHENG Chun-Quan, ZHOU You-Jun, ZHU Ju, LÜ Jia-Guo*

Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received:2009-03-18 Online:2009-12-10 Published:2009-12-10
Contact: Lü Jia-Guo. E-mail: ljg20060508@yahoo.com.cn
Supported by:
上海市计生委科研基金(批准号: 2007JG02)和上海市重点学科建设项目(批准号: B906)资助.

摘要/Abstract

摘要：

顶体酶是目前抗生育药物的一个潜在靶点. 在前期同源模建人顶体酶三维结构复合物的基础上, 采用多重拷贝同时搜寻(MCSS)等方法对人顶体酶活性腔进行分析. 结果显示, 活性腔的P1,P2和G 3个区域均具有较大极性, 且P1对抑制剂结合尤为重要. 另外, G和P1边缘及P2底部还具有一定疏水性, 且其中的部分重要残基还能与配体形成氢键作用和静电作用. MCSS计算结果确定的关键配体结合位点与人顶体酶复合物结构和定点突变实验结果相吻合. 在此基础上用分子对接方法将6个人顶体酶代表性抑制剂对接入活性腔, 阐明其结合模式, 确定与配体结合相关的关键残基.

关键词: 顶体酶; 多重拷贝同时搜寻; 抑制剂; 抗生育药物(KF950); 分子对接

Abstract:

Acrosin is a promising target for contraceptive agents. Based on the previous homology modeling of human acrosin, the multiple copy simultaneous search(MCSS) methodology was used to explore the active site of human acrosin. The results show that all of three subsites(P1, P2 and G) are polar zones, and P1 is crucial for inhibitors′ binding. In addition, the edge of P1 and G as well as the bottom of P2 are hydrophobic, in which several important residues form hydrogen-binding interactions and electrostatic interactions. The key residues for ligand binding confirmed by MCSS calculations were consistent with the 3D structure of human acrosin complex and the experiments of site-directed mutagenesis on the animals. On the basis of above results, six of acrosin inhibitors, were docked into the active site of the human acrosin to elucidate their binding mode and the critical residues involved in binding. Our studies provide a basis for the rational design of novel acrosin inhibitors and the discovery of novel contraceptive drugs with high potency.

Key words: Acrosin; Multiple copy simultaneous search; Inhibitor; Contraceptive drug(KF950); Docking

TrendMD:

张珏, 郑灿辉, 盛春泉, 周有骏, 朱驹, 吕加国. 人顶体酶活性腔性质及与抑制剂的结合模式. 高等学校化学学报, 2009, 30(12): 2409.

ZHANG Jue, ZHENG Can-Hui, SHENG Chun-Quan, ZHOU You-Jun, ZHU Ju, Lü Jia-Guo*. Characterization of Human Acrosin Active Site and Binding Modes with Its Inhibitors. Chem. J. Chinese Universities, 2009, 30(12): 2409.

参考文献

[1]Yamagata K., Murayama K., Okabe M., et al.. J. Biol. Chem.[J], 1998, 273(17): 10470—10474
[2]Zahler W. L., Polakoski S. L.. Biochim. Biophys. Acta[J], 1977, 480(2): 461—468
[3]Fraser L. R.. Reprod. Fert.[J], 1982, 65(1): 185—194
[4]LÜ Jia-Guo(吕加国), ZHAO Ya-Nan(赵亚南), ZHOU You-Jun(周有骏), et al.. Preparation of 4-Guanidino-benzoic Acid-4-(methoxycarbonyl)phenyl Ester Monomesylate as Contraceptive Agent(一种抗生育化合物及其制备方法), CN 1438217[P], 2003
[5]ZHONG Wei-Guo(仲伟国), ZHAO Ya-Nan(赵亚南), JI Ya-Zhong(纪亚忠), et al.. Reproduction & Contraception(生殖与避孕)[J], 2000, 20(5): 333—337
[6]ZHAO Ya-Nan(赵亚南), JI Ya-Zhong(纪亚忠), L Jia-Guo(吕加国), et al.. Reproduction & Contraception(生殖与避孕)[J], 2000, 20(5): 294—296
[7]ZHAO Ya-Nan(赵亚南), JI Ya-Zhong(纪亚忠), L Jia-Guo(吕加国), et al.. Chinese J. Andrology(中国男科学杂志)[J], 2000, 14(3): 149—151
[8]ZHAN Ying(詹瑛), ZHAO Ya-Nan(赵亚南), LI Zong-Lin(李宗林), et al.. National J. Andrology(中华男科学杂志)[J], 2002, 8(2): 92—94
[9]Tranter R., Read J. A., Jones R., et al.. Structure[J], 2000, 8(11): 1179—1188
[10]LÜ Jia-Guo(吕加国), SHENG Chun-Quan(盛春泉), ZHANG Min(张珉), et al.. Acta Chin. Sinica(化学学报)[J], 2006, 64(10): 1073—1078
[11]Miranker A., Karplus M.. Protein[J], 1991, 11(11): 29—34
[12]SONG Gui-Hong(宋桂红). Sperm Morphological and Functional Modification by Synthetic Acrosin Inhibitor(顶体酶抑制剂对精子形态及功能的影响)[D], Shanghai, Second Military Medical University, 2007
[13]Sumi H., Toki N.. Experientia[J], 1980, 36(9): 1103—1104
[14]Kaminski J. M., Bauser L., Mack S. R., et al.. J. Med. Chem.[J], 1986, 29(4): 514—519
[15]Gupta G., Jain R. K., Maikhuri J. P., et al.. Hum. Repord.[J], 2005, 20 (8): 2301—2308
[16]Insight II, Computer Program, Version 2000[CP], San Diego, CA: Accelrys Inc., 2000
[17]SYBYL, Computer Program, Version 6.9[CP], St. Louis, MO: Tfipos Associates Inc., 1999
[18]Morris G. M., Goodsell D. S., Halliday R. S., et al.. J. Comput. Chem.[J], 1998, 19(14): 1639—1662
[19]Evensen E., Joseph-McCarthy D., Weiss G. A., et al.. J. Conput. Aided Mol. Des.[J], 2007, 21(7): 395—418
[20]Jansen S., Jones R., Jennecken I., et al.. Mol. Repord. Dev.[J], 1998, 51(2): 184—192
[21]Okutome T., Kawamura H., Taira S., et al.. Chem. Pharm. Bull.[J], 1984, 32(5): 1854—1865